Hosted on MSN2h
Nearly 1.4 Million Over-the-Counter Eye Drops Recalled at FDA’s Highest Risk Level
A couple drops in your eye usually brings relief, not concern—but a rare recall case highlights the importance of a clean, sterile bottle.
USA Today1mon
Eye drops recalled over fungal concerns: Here's which Systane products are impacted
Select eye drops under the Systane brand were voluntarily ... foreign material in a sealed single-use vial of the eye drop solution, according to the recall announcement. The company determined ...
Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care
Oculis' main value driver appears to be OCS-01, which targets a respectable $4B DME TAM with its non-invasive eye drops. See ...
Future Market Insights6d
Revolutionizing Eye Care: Ophthalmic Sprays Market Poised to Reach USD 783.3 Million by 2033
The global ophthalmic sprays market, valued at USD 343 million in 2023, is projected to experience exponential growth, ...
Business Insider10d
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
About XDEMVY ® XDEMVY (lotilaner ophthalmic solution, 0.25%), formerly known as TP-03, is a novel prescription eye drop designed to treat Demodex blepharitis by targeting and eradicating the root ...
bovnews1d
What’s Causing National Vision Holdings Inc (EYE) Stock’s -20.88% Drop Over the Last Six Months?
National Vision Holdings Inc (EYE) stock saw a modest uptick, ending the day at $10.8 which represents a slight increase of $0.05 or 0.47% from the prior close of $10.75. The stock opened at $11 and ...